Pharmaceuticals

Gan & Lee Pharmaceuticals Announces Significant Progress on New Diabetes and Obesity Treatments at the American Diabetes Association's 84th Scientific Sessions

BEIJING and BRIDGEWATER, N.J., June 23, 2024 /PRNewswire/ -- Gan & Lee Pharmaceuticals (Gan & Lee, Shanghai Stock Exchange: 603087) announced the results of the Phase1b/2a clinical study of the Company's independently developed glucagon-like peptide-1 (GLP-1) receptor agonist, GZR18 Injection, in...

2024-06-23 21:09 5610

Sciwind Biosciences to Highlight Positive Results for Injectable Ecnoglutide (Phase 3), Oral Ecnoglutide (Phase 1), and Novel Amylin Analogs at the American Diabetes Association (ADA) 84th Annual Conference

* A Phase 1 study of oral ecnoglutide (1871-LB) showed it to be safe and well tolerated and result in pronounced weight loss (up to -6.76% after 6 weeks of dosing). Improved oral bioavailability enables a 15 to 30 mg daily dose of oral ecnoglutide to match or exceed the plasma exposure of weekl...

2024-06-22 07:00 7397

Biocytogen Awarded U.S. Patent for RenLite® Common Light Chain Mouse Platform

BEIJING, June 21, 2024 /PRNewswire/ -- Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) announced United States Patent and Trademark Office (USPTO) patent grant for independently developed RenLite® fully human common light chain mouse platform.

2024-06-21 17:45 9877

Ascentage Pharma Announces Closing of US$75 Million Equity Investment by Takeda

ROCKVILLE, Md. and SUZHOU, China, June 21, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that the agreed equity investment by Takeda has bee...

2024-06-21 09:19 6285

Clarivate Identifies Seven Innovators in Antibody Drug Conjugates in New Companies to Watch Report

Emerging standouts set to transform drug discovery and development, revolutionize cancer treatment, and capture big pharma interest highlighted in third annual report LONDON, June 19, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, has re...

2024-06-19 15:00 2450

Innovent Reports Oncology Pipeline Updates at Investor Meeting

SAN FRANCISCO and SUZHOU, China, June 19, 2024 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and o...

2024-06-19 10:55 6571

Menarini Asia-Pacific partners with Pharmacosmos to expand its reach of MonoFer® to Singapore and Malaysia

SINGAPORE, June 19, 2024 /PRNewswire/ -- Menarini Asia-Pacific (Menarini) today announced that it has expanded its partnership with Pharmacosmos A/S (Pharmacosmos), to include exclusive rights to commercialiseMonoFer® (ferric derisomaltose) in Singapore and Malaysia. This builds upon the successf...

2024-06-19 09:43 3388

Clover Announces Positive Preliminary Phase Ⅰ Results for Bivalent RSV Vaccine Candidate SCB-1019 in Older Adults

-- Bivalent SCB-1019 significantly boosted RSV-A and RSV-B neutralizing antibody titers in older adults up to approximately 7,900 IU/mL (up to 8-fold increase) and approximately 46,700 IU/mL (up to 11-fold increase), respectively -- -- Favorable safety & reactogenicity profile comparable to sali...

2024-06-18 17:41 4634

Diplomatic Envoys to China Visit Fosun: Appreciating Oriental Lifestyle Aesthetics and Seeking Opportunities for Business Cooperation

SHANGHAI, June 18, 2024 /PRNewswire/ -- Over 40 guests, including 10 ambassadors toChina, 8 consuls general and other senior diplomats from 26 countries, visited Fosun on 14 June. The delegation toured along the Grand Yuyuan. From the intangible cultural heritage of the Old City of Shanghai to t...

2024-06-18 12:53 5024

Live from EHA 2024 | Ascentage Pharma Releases Updated Data of Lisaftoclax in Patients with R/R MM and AL Amyloidosis Highlighting Marked Improvement in ORR

SUZHOU, China and ROCKVILLE, Md., June 18, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that it has released updated data of the Bcl-2 inh...

2024-06-18 12:43 4073

Live from EHA 2024 | Posters Featuring Results from Three Studies of Olverembatinib, Including Encouraging Data from US Study in CML and Ph+ ALL

SUZHOU, China and ROCKVILLE, Md., June 18, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that updated results from three studies of olverem...

2024-06-18 12:23 3775

Gan & Lee Pharmaceuticals to Present Groundbreaking Data on Three Innovative Products at the American Diabetes Association's 84th Scientific Sessions

* A phase 1b/2a trial evaluated once- and bi-weekly GZR18, a novel GLP-1 analog, in Chinese subjects with obesity/overweight * Pre-clinical studies evaluated the molecular and pharmacological properties of GZR4, an investigational once-weekly insulin analog  * Pre-clinical studies evaluated ...

2024-06-18 12:13 4563

Faculty of Medicine Siriraj Hospital and Dhulikhel Hospital commemorate 15 years of collaborative relationship

BANGKOK, June 17, 2024 /PRNewswire/ -- In 2024, Thai-Nepalese bilateral relations reached a new milestone as the Faculty of Medicine Siriraj Hospital at Mahidol University inThailand and Dhulikhel Hospital at Kathmandu University inNepal celebrated the 15th anniversary of their esteemed partnersh...

2024-06-17 15:04 3023

Ascentage Pharma Signs Option Agreement with Takeda to Enter into Exclusive Global License for Olverembatinib, a Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI)

* Ascentage Pharma has executed an Exclusive Option to License Global Rights to Olverembatinib worldwide other thanChina and a few other areas. * Ascentage Pharma to receive an option payment of 100 million USD upon closing and be eligible for an option exercise fee and additional potential m...

2024-06-14 21:30 10654

Innovent Delivers Oral Presentation on Clinical Data of IBI363 (First-in-class PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) in Advanced Non-small Cell Lung Cancer and Other Solid Tumors at the 2024 ESMO Virtual Plenary

SAN FRANCISCO and SUZHOU, China, June 14, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology ...

2024-06-14 08:34 8803

Ethypharm expands its Mesalazine (Etiasa®) Portfolio in China

SAINT-CLOUD, France, June 13, 2024 /PRNewswire/ -- Ethypharm is pleased to announce the acquisition of a suppository form of Mesalazine by its Chinese affiliate, Shanghai Ethypharm Pharmaceuticals Ltd, from the Chinese Company Jiangsu Anbison Pharmaceutical. Leader in essential medicines for cen...

2024-06-13 22:33 3187

Sirnaomics Demonstrates Strong Antitumor Activity of Its Novel Oligonucleotide-ChemoDrug Conjugate in Journal of Oncology Research and Therapy

HONG KONG, GERMANTOWN, Md. and SUZHOU, China, June 13, 2024 /PRNewswire/ -- Sirnaomics Ltd.(the "Company"; together with its subsidiaries, "Sirnaomics" or the "Group"; stock code: 2257), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, today announced that th...

2024-06-13 18:03 4547

Innovent Receives Fast Track Designation from the U.S. FDA for IBI343 (TOPO1i anti-CLDN18.2 ADC) as Monotherapy for Advanced Pancreatic Cancer

SAN FRANCISCO and SUZHOU, China, June 13, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune...

2024-06-13 08:00 6373

Ansell Recognized with the Frost & Sullivan 2024 Global Company of the Year Award for Revolutionizing Workplace Safety and Promoting Sustainability

Ansell is committed to ensuring the safety and well-being of workers worldwide with an extensive range of safety solutions that meet the specific needs of clinicians and healthcare providers. SAN ANTONIO, June 12, 2024 /PRNewswire/ -- Frost & Sullivan recently researched and conducted a review o...

2024-06-12 21:00 2603

Latest Updates of Viva Biotech's Portfolio Companies

HONG KONG, June 12, 2024 /PRNewswire/ -- Even with the ever-changing situation, technological innovation is still the most critical component for biopharmaceutical companies' long-term development. This continuous innovation keeps companies up to date and promotes the evolution of R&D and the suc...

2024-06-12 19:51 4104
1 ... 71727374757677 ... 184